HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) issued its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60), Morningstar.com reports. The firm had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.80 million. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%.
HTG Molecular Diagnostics (HTGM) traded down 2.34% during mid-day trading on Friday, hitting $2.09. The stock had a trading volume of 150,426 shares. The company’s market cap is $23.93 million. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25. The company has a 50-day moving average price of $2.34 and a 200 day moving average price of $3.37.
ILLEGAL ACTIVITY WARNING: This story was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/20/htg-molecular-diagnostics-inc-nasdaqhtgm-announces-quarterly-earnings-results-meets-estimates-updated.html.
A number of equities analysts have issued reports on the company. Zacks Investment Research lowered HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of HTG Molecular Diagnostics in a research note on Thursday, June 29th. Rodman & Renshaw raised their price objective on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, May 16th. Finally, ValuEngine raised HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Monday, July 17th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. HTG Molecular Diagnostics currently has an average rating of “Hold” and an average price target of $5.75.
A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Vanguard Group Inc. boosted its stake in shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) by 38.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the period. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.26% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.